Aspen Phamacare said on Thursday the Competition and Markets Authority of the UK had confirmed its decision to impose a fine of about £2.1m (R45m) on the group.
Aspen had said in August it had reached a settlement and admitted liability for entering into an agreement to acquire a potential competitor, which relates to the supply of fludrocortisone in the UK.
Under that agreement, the £2.1m fine is the maximum penalty that could be imposed.
Aspen said on Thursday this brought the matter to a close.
In morning trade, the group’s share was down 1.5% to R146.98, on track for its worst one-day performance in about two weeks. — BusinessLIVE
Would you like to comment on this article or view other readers' comments? Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.